{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:52:07Z","timestamp":1787028727874,"version":"build-2736575974"},"reference-count":47,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer","award":["71177147"],"award-info":[{"award-number":["71177147"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among immunocompromised patients with underlying malignancies and prior transplants. FDA approved Isavuconazole as a primary therapy for Invasive Aspergillosis (IA) and Mucormycosis. This study aims to compare the real-world clinical outcomes and safety of isavuconazole to voriconazole and an amphotericin B-based regimen in patients with underlying malignancies and a transplant. In addition, the response to anti-fungal therapy and the outcome were compared among patients with a disparity (elderly, obese patients, patients with renal insufficiency and diabetes mellitus) versus those with no disparity. We performed a multicenter retrospective study, including patients with cancer diagnosed with an invasive fungal infection, and treated primarily with isavuconazole, voriconazole or amphotericin B. Clinical, radiologic findings, response to therapy and therapy related adverse events were evaluated during 12 weeks of follow-up. We included 112 patients aged 14 to 77 years, and most of the IFIs were classified into definite (29) or probable (51). Most cases were invasive aspergillosis (79%), followed by fusariosis (8%). Amphotericin B were used more frequently as primary therapy (38%) than isavuconazole (30%) or voriconazole (31%). Twenty one percent of the patients presented adverse events related to primary therapy, with patients receiving isavuconazole presenting less adverse events when compared to voriconazole and amphotericin (p &lt; 0.001; p = 0.019). Favorable response to primary therapy during 12 weeks of follow-up were similar when comparing amphotericin B, isavuconazole or voriconazole use. By univariate analysis, the overall cause of mortality at 12 weeks was higher in patients receiving amphotericin B as primary therapy. However, by multivariate analysis, Fusarium infection, invasive pulmonary infection or sinus infection were the only independent risk factors associated with mortality. In the treatment of IFI for patients with underlying malignancy or a transplant, Isavuconazole was associated with the best safety profile compared to voriconazole or amphotericin B-based regimen. Regardless of the type of anti-fungal therapy used, invasive Fusarium infections and invasive pulmonary or sinus infections were the only risk factors associated with poor outcomes. Disparity criteria did not affect the response to anti-fungal therapy and overall outcome, including mortality.<\/jats:p>","DOI":"10.3390\/jof9020166","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T02:28:34Z","timestamp":1675045714000},"page":"166","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-0873","authenticated-orcid":false,"given":"Marjorie Vieira","family":"Batista","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, AC Camargo Cancer Center, S\u00e3o Paulo 01509-010, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Piedad","family":"Ussetti","sequence":"additional","affiliation":[{"name":"Transplant Department, Puerta de Hierro University Hospital, 28222 Majadahonda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6970-2869","authenticated-orcid":false,"given":"Dionysios","family":"Neofytos","sequence":"additional","affiliation":[{"name":"Transplant Department, University Hospital of Geneva, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita Cassoli","family":"Cortez","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, AC Camargo Cancer Center, S\u00e3o Paulo 01509-010, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3733-6048","authenticated-orcid":false,"given":"Diego","family":"Feriani","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, AC Camargo Cancer Center, S\u00e3o Paulo 01509-010, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayr","family":"Schmidt-Filho","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, AC Camargo Cancer Center, S\u00e3o Paulo 01509-010, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Leonardo Avelino","family":"Fran\u00e7a-Silva","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, AC Camargo Cancer Center, S\u00e3o Paulo 01509-010, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam","family":"Raad","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8940-0793","authenticated-orcid":false,"given":"Ray","family":"Hachem","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/myc.12212","article-title":"Treatment and outcomes of invasive fusariosis: Review of 65 cases from the PATH Alliance\u00ae registry","volume":"57","author":"Horn","year":"2014","journal-title":"Mycoses"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jinf.2012.08.003","article-title":"Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry","volume":"65","author":"Steinbach","year":"2012","journal-title":"J. Infect."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bbmt.2015.03.018","article-title":"Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: A multicenter prospective observational study","volume":"21","author":"Sun","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1086\/652768","article-title":"Factors Associated with Mortality in Transplant Patients with Invasive Aspergillosis","volume":"50","author":"Baddley","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e00399-19","DOI":"10.1128\/AAC.00399-19","article-title":"Echinocandins for the Treatment of Invasive Aspergillosis: From Laboratory to Bedside","volume":"63","author":"Aruanno","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: A phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sarfati, S., Wils, J., Lambert, T., Mory, C., Imbert, L., Gargala, G., Morisse-Pradier, H., and Lamoureux, F. (2022). Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081598"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/jof6040324","article-title":"Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance","volume":"6","author":"Ellsworth","year":"2020","journal-title":"J. Fungi"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2012.761135","article-title":"Optimizing antifungal choice and administration","volume":"29","author":"Andes","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: Practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101304","DOI":"10.1016\/j.mycmed.2022.101304","article-title":"Impact of revised EORTC\/MSGERC 2020 criteria on diagnosis and prognosis of invasive pulmonary aspergillosis in patients with hematological malignancies undergoing bronchoscopy","volume":"32","author":"Kazak","year":"2022","journal-title":"J. Mycol. Med."},{"key":"ref_19","unstructured":"Batista, M.V. (2015). Aspergilose Invasiva em Pacientes Imunodeprimidos: Compara\u00e7\u00e3o Entre as Provas de Galactomanana, 1, 3 betaD-Glucana, dados Tomogr\u00e1ficos e Desfecho Cl\u00ednico, Universidade de S\u00e3o Paulo."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/cid\/ciaa205","article-title":"Validation by Real-life Data of the New Radiological Criteria of the Revised and Updated Consensus Definition for Invasive Fungal Diseases","volume":"71","author":"Herbrecht","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hsu, L.Y., Ding, Y., Phua, J., Koh, L.P., Chan, D.S., Khoo, K.L., and Tambyah, P.A. (2010). Galactomannan testing of bronchoalveolar lavage fluid is useful for diagnosis of invasive pulmonary aspergillosis in hematology patients. BMC Infect. Dis., 10.","DOI":"10.1186\/1471-2334-10-44"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Linder, K.A., Kauffman, C.A., and Miceli, M.H. (2020). Performance of Aspergillus Galactomannan Lateral Flow Assay on Bronchoalveolar Lavage Fluid for the Diagnosis of Invasive Pulmonary Aspergillosis. J. Fungi, 6.","DOI":"10.3390\/jof6040297"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11046-020-00479-0","article-title":"Performance of the (1,3)-Beta-D-Glucan Assay on Bronchoalveolar Lavage Fluid for the Diagnosis of Invasive Pulmonary Aspergillosis","volume":"185","author":"Linder","year":"2020","journal-title":"Mycopathologia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-6515-1_2","article-title":"The Changing Epidemiology of Invasive Fungal Infections","volume":"1508","author":"Enoch","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11046-017-0115-y","article-title":"Risk Factors and Outcomes of Invasive Fungal Infections in Allogeneic Hematopoietic Cell Transplant Recipients","volume":"182","author":"Miceli","year":"2017","journal-title":"Mycopathologia"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Harrison, N., Mitterbauer, M., Tobudic, S., Kalhs, P., Rabitsch, W., Greinix, H., Burgmann, H., Willinger, B., Presterl, E., and Forstner, C. (2015). Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: A retrospective cohort study. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-1329-6"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e12981","DOI":"10.1111\/tid.12981","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study","volume":"20","author":"Kuster","year":"2018","journal-title":"Transpl. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/ejh.12426","article-title":"Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: Real-life data from a retrospective single-centre observational study","volume":"94","author":"Nachbaur","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"ofz176","DOI":"10.1093\/ofid\/ofz176","article-title":"Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy","volume":"6","author":"Patel","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Dagher, H., Hachem, R., Chaftari, A.M., Jiang, Y., Ali, S., Deeba, R., Shah, S., and Raad, I. (2022). Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant. J. Fungi, 8.","DOI":"10.3390\/jof8010074"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/1469-0691.12409","article-title":"Improvement in the outcome of invasive fusariosis in the last decade","volume":"20","author":"Nucci","year":"2014","journal-title":"Clin Microbiol. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2147\/DDDT.S354270","article-title":"Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies","volume":"16","author":"Zhao","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s11095-022-03289-9","article-title":"Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax","volume":"39","author":"Dong","year":"2022","journal-title":"Pharm. Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Garrison, D.A., Jin, Y., Talebi, Z., Hu, S., Sparreboom, A., Baker, S.D., and Eisenmann, E.D. (2022). Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B. Molecules, 27.","DOI":"10.3390\/molecules27206815"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2352-3026(21)00232-5","article-title":"Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs","volume":"9","author":"Verheggen","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2352-3026(22)00073-4","article-title":"Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: A systematic review and expert consensus recommendation from the European Hematology Association","volume":"9","author":"Stemler","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/jcph.1094","article-title":"Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects","volume":"58","author":"Marshall","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e00274-21","DOI":"10.1128\/AAC.00274-21","article-title":"Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir","volume":"65","author":"Terrier","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mycmed.2018.02.002","article-title":"Isavuconazole: A new broad-spectrum azole. Part 2, Pharmacokinetics and clinical activity","volume":"28","author":"Ledoux","year":"2018","journal-title":"J. Mycol. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","article-title":"New Perspectives on Antimicrobial Agents: Isavuconazole","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/phar.1652","article-title":"Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent","volume":"35","author":"Rybak","year":"2015","journal-title":"Pharmacotherapy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/14737167.2021.1981862","article-title":"Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada","volume":"22","author":"Beauchemin","year":"2022","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e0042522","DOI":"10.1128\/spectrum.00425-22","article-title":"Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom","volume":"10","author":"Earnshaw","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Floros, L., Kuessner, D., Posthumus, J., Bagshaw, E., and Sj\u00f6lin, J. (2019). Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3683-2"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12325-016-0443-1","article-title":"Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis","volume":"34","author":"Harrington","year":"2017","journal-title":"Adv. Ther."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/2\/166\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:16:51Z","timestamp":1760120211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/2\/166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["jof9020166"],"URL":"https:\/\/doi.org\/10.3390\/jof9020166","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]}}}